Two years after an FDA rejection sent Delcath Systems spiraling, the company has reached an agreement with the regulatory agency to move its once-rejected drug-device combo forward.
The biotech announced Jan. 19 that it has established a special protocol assessment (SPA) for its Phase III trial of...
Welcome to Scrip
Create an account to read this article
Already a subscriber?